Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.20.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue [1],[2] $ 9,469 $ 10,525 $ 16,621 $ 19,154
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 9,469 10,525 16,621 19,154
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,509 1,670 3,554 3,245
Collaboration and License Agreements and Supply Agreements | Merck        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 7,005 5,497 9,782 10,132
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 100 0 136 281
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 855 $ 3,358 $ 3,149 $ 5,496
[1] Includes $0 and $2.8 million, respectively, for the three months and six months ended June 30, 2020 of related party revenue from Merck. Merck was a related party until the closing of the Company’s public offering on May 14, 2020.
[2] Includes $0 and $36,000, respectively, for the three months and six months ended June 30, 2020 of related party revenue from Vaxcyte (formerly SutroVax). Vaxcyte was a related party until the closing of its initial public offering on June 16, 2020.